Here are the G-BA decisions from the G-BA meeting held on 20 April 2023 on the early benefit assessments of Ultomiris, Genvoya, Lynparza, and Evusheld.
A complete database of all previous G-BA resolutions is available through my membership.
- Ultomiris (ravulizumab); new indication: Myasthenia gravis, AChR antibodies+ – Additional benefit not proven; resolution restricted until 1 Nov 2023
- Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide); new indication: HIV infection, patients aged 2 to < 6 years – Additional benefit not proven in both subgroups
- Lynparza (olaparib); re-assessment after expiry of previous decision: ovarian, fallopian tube, or primary peritoneal; maintenance after first-line therapy; HRD-positive; combination with bevacizumab – Hint of considerable additional benefit
- Evusheld (tixagevimab/cilgavimab); first-time dossier obligation: COVID-19, increased risk of severe course, patients aged ≥ 12 years – Hint of minor additional benefit in one of three subgroups
Follow me on Instagram to never miss the latest G-BA decisions (here 20 April 2023):